Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics (Nasdaq: AKBA) will release first-quarter 2026 financial results for the period ended March 31, 2026, on Thursday, May 7, 2026, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) will release first-quarter 2026 financial results for the period ended March 31, 2026, on Thursday, May 7, 2026, before market open. A conference call to discuss results and recent business highlights is scheduled for May 7, 2026 at 8:00 a.m. EDT, with a live webcast and archived replay available via the Investors section of Akebia's website.
Details
News Market Reaction – AKBA
On May 1, the first trading day after this news, AKBA closed 1.45% above the previous close.
Data tracked by StockTitan Argus for the May 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026, prior to the open of financial markets.
Akebia will host a conference call on Thursday, May 7, 2026, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.